MEI Pharma Inc. (NASDAQ:MEIP) was up 2.9% on Tuesday . The company traded as high as $2.13 and last traded at $2.10, with a volume of 1,067,060 shares. The stock had previously closed at $2.04.

A number of equities research analysts have recently weighed in on MEIP shares. Wedbush restated a “neutral” rating and set a $2.00 target price on shares of MEI Pharma in a research report on Tuesday, August 2nd. Zacks Investment Research raised MEI Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, July 6th.

The company’s market capitalization is $70.02 million. The company has a 50 day moving average price of $1.59 and a 200 day moving average price of $1.39.

MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.